Please ensure Javascript is enabled for purposes of website accessibility

Why DermTech Stock Was Climbing Today

By Jeremy Bowman - Updated Apr 27, 2021 at 1:01PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

News that Cigna was covering its new skin cancer patch helped send the stock higher.

What happened

Shares of DermTech (DMTK 7.97%) were climbing on Tuesday after Cigna said it would begin covering the biotech company's early-detection skin cancer test.

Shares were up 15.9% as of 11:48 a.m. EDT today on the news.

The DermTech PLA adhesive patch

The DermTech PLA patch. Image source: DermTech.

So what

Virtually all of the value for DermTech, an early-stage genomics company, is tied to forecasts for its Pigmented Lesion Assay (PLA), an adhesive patch that offers a noninvasive way of detecting melanoma, disrupting conventional biopsies that require a skin sample and testing in a lab. That Cigna, a health insurance company worth nearly $100 billion, is now covering the patch represents a significant step forward for the technology as it hopes to gain widespread adoption.

Cigna covers about 10% of the U.S. commercial market, and became the first national carrier to cover the PLA with the move.

Craig-Hallum analyst Alex Nowak issued a note saying that the news should help reverse DermTech stock's recent weakness, and reiterated a buy rating with a price target at $70.

Now what

In January, the PLA received a recommendation from the National Comprehensive Cancer Network, paving the way for insurers to cover the product, and Cigna should be followed by more of its peers.

DermTech shares soared early in the year on anticipation for the PLA and on a surge in growth stocks before fading over the last two months. High expectations are baked in as the company is now valued at $1.3 billion even though it only brought in $5 million in revenue in its most recent quarter. DermTech has estimated an addressable market in skin cancer of as much as $10 billion, so the biotech stock should have a lot of upside if the PLA gains wide adoption.

 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

DermTech, Inc. Stock Quote
DermTech, Inc.
DMTK
$5.96 (7.97%) $0.44

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.